Bristol-Myers Squibb and Celgene have agreed to sell off Celgene’s psoriasis treatment Otezla (apremilast) to resolve the Federal Trade Commission’s concerns that BMS’s proposed $74 billion acquisition of Celgene would create a monopoly for oral moderate-to-severe psoriasis treatments.